becton dickinson co februari
becton dickinson co
strong start growth across segment
recommend buy rate tp
deriv tp base non-gaap ep
forward price-to-earnings multipl provid
upsid potenti expect
top-lin revenu growth
estim base follow factor strong
revenu growth across three segment acquisit
new product pipelin
perform reflect strong start
report growth revenu due growth across
three segment ep increas
due gain sale advanc
bioprocess busi net expens relat tax
reform prior-year period adjust ep
revenu emerg market grew
perform driven growth china
double-digit growth latin america partial off-set ema
growth china reflect strength across life scienc
intervent segment perform
medic segment china strong due geographi
order pharmaceut system
bd medic revenu increas
revenu medic deliveri solut grew
led strength vascular assess infus
dispos revenu medic manag
solut grew due stronger
expect capit placement infus
compani namebecton dickinson cotickerbdxstock ratingbuyunchangedindustri viewoverweightpositivepric feb week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth yoy n/acrispideaakansha becton dickinson co februari
incom statement
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
becton dickinson co februari
diabet revenu grew
growth impact time distributor order
 time tender ema
revenu pharmaceut system grew due
strong demand core product continu
growth sai
revenu diagnost system grew
perform driven instrument
microbiolog platform includ blood cultur
idast bd molecular platform
bioscienc revenu grew
growth driven research reagent well growth
newer instrument facslyr
perform bioscienc reflect unfavor
time tender ema
revenu urolog critic grew
perform ucc driven new
product acut care urolog well strength
home care target temperatur manag
current price-to-earnings slightli averag
price-to-earnings due fall stock price
quarter price-to-earnings trail averag
octob price-to-earnings trail
avg-stdev past
year expect forward price-to-earnings multipl
recommend buy rate tp
expect growth revenu base
 bard acquisit strong product pipelin
stock price histori date high obsolet date obsolet move move share statist averag volum averag volum share held held share short short share short prior month error dividend split forward annual dividend forward annual dividend trail annual dividend trail annual dividend year averag dividend pay-out dividend date ex-dividend date last split factor new per last split date aug inform becton dickinson co februari
incom statement
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
becton dickinson co februari
non- reconcili refer page
incom statement total gross research sale gener restructur merger oper total oper oper interest incom incom provis incom net prefer net incom avail common weight averag share estim annual actual annual actual quarterli becton dickinson co februari
prepaid current total current net properti plant equiti intang long-term total non-curr total short-term account tax accru current total current long-term defer tax long-term total non-curr total prefer common addit paid-in retain treasuri accumul comprehens total stockhold total liabil stockhold balanc sheet itemsactu annual actual quarterli becton dickinson co februari
flow oper activ compar
reflect net incom adjust chang oper asset liabil net use cash
provid invest activ compar cash use invest
activ
use financ activ compar cash provid financ
activ
depreci defer incom stock base chang work account prepaid work non-cash net cash provid oper invest properti plant acquisit purchas sales/matur invest net cash use invest chang credit facil debt debt common stock common stock excess tax benefit stock base dividend financ net cash provid use financ effect exchang rate net chang begin end becton dickinson co februari
becton dickinson co deliv strong perform quarter
growth revenu due acquisit bard strong
compar
due acquisit
 bard growth
across segment
total revenu increas compar
due acquisit bard growth across
segment currency-neutr basi revenu increas prior-
total revenu increas compar
total intern revenu increas
compar
compar
cog increas compar
gross margin decreas compar
sg expens increas compar
adjust sg expens revenu
compar increas due higher
sg cost larg driven inclus bard higher sell
administr spend profil current-year result
 expens increas compar
adjust expens revenu
compar expens reflect continu
commit invest new product platform
acquisit restructur cost increas
compar oper incom increas
compar adjust
oper margin increas compar
becton dickinson co februari
interest expens increas compar
interest incom net declin
compar incom
compar expens
incom tax provis declin compar
adjust tax rate compar
net incom compar net loss
adjust net incom increas
compar
gaap ep increas compar
non-gaap ep increas compar
net incom
compar
net loss
compar
becton dickinson co februari
total revenu increas
compar revenu growth benefit
inclus revenu associ bard product result
total intern revenu increas
compar revenu growth also benefit
inclus revenu associ bard product financi
growth revenu driven increas sale medic segment
medic deliveri solut pharmaceut system unit well
strong revenu life scienc segment preanalyt system unit
emerg market revenu increas
compar emerg market revenu also includ
estim unfavor impact due foreign currenc translat
emerg market benefit inclus revenu associ
bard product financi result
emerg market growth also due increas sale china latin
america total revenu china increas
develop market revenu increas
total revenu
 increas
compar
revenu increas
compar
 becton dickinson co februari
bdx organiz structur base upon three princip busi segment
bd medic bd life scienc bd intervent
total revenu medic segment increas
compar medic segment growth
favor impact inclus revenu associ certain
bard product within medic deliveri solut unit
medic segment revenu growth driven medic
manag solut unit instal infus system
pharmaceut system unit sale prefil product
medic segment growth also benefit medic
deliveri solut unit sale vascular access infus dispos
product sale diabet unit unfavor impact
delay order time ema
total revenu increas
compar total intern revenu increas
compar
oper incom increas compar
oper margin increas
compar
total revenu medic deliveri solut increas
compar total revenu
 increas compar
total intern revenu increas
compar
total revenu
increas
compar
total revenu
solut increas
compar
becton dickinson co februari
total revenu medic manag solut increas
compar total
revenu increas
compar total intern revenu increas
compar
total revenu diabet care decreas
compar total revenu
 decreas compar
total intern revenu declin
compar
total revenu pharmaceut system increas
compar total revenu
 increas compar
total intern revenu increas
compar
total revenu life scienc segment decreas
compar life scienc segment
revenu growth due preanalyt system unit global sale
diagnost system unit revenu driven sale core
microbiolog product well continu strength sale unit bd
total revenu
increas
compar
total revenu life
decreas
compar
becton dickinson co februari
bioscienc unit revenu reflect growth instrument reagent
sale unfavor impact divestitur advanc
associ advanc bioprocess busi
total revenu increas
compar total intern revenu decreas
compar
oper incom compar
oper margin compar
total revenu preanalyt increas
compar total revenu
 increas compar
total intern revenu increas
compar
total revenu
increas
compar
total revenu
bioscienc decreas
compar
total revenu diagnost system increas
compar total revenu
 increas compar
total intern revenu decreas
compar
total revenu bioscienc decreas
compar total revenu
flat compar total intern
revenu decreas compar
total revenu
increas
compar
total revenu
increas
compar
becton dickinson co februari
total revenu intervent segment increas
compar segment result
reflect strong perform surgeri urolog critic
unit growth peripher intervent unit reflect tough
comparison prior-year period
total revenu increas compar
total intern revenu increas
compar
oper incom increas compar
oper margin compar
total revenu surgeri busi increas
compar total revenu increas
compar total
intern revenu increas compar
total revenu peripher intervent increas
compar total revenu
increas compar total
intern revenu increas compar
urolog critic
total revenu urolog critic busi
total revenu total
intern revenu
becton dickinson co februari
becton dickinson co februari
total revenu
expect grow
rang
ssg sale
 sale
adjust ep growth
expect
total revenu expect grow rang
adjust ep growth expect
effect tax rate expect
gross margin expect
oper expect
becton dickinson co februari
report strong result due acquisit bard
growth across segment total revenu increas
ep increas due gain
sale advanc bioprocess busi net expens relat
tax reform prior-year period adjust ep
bd medic segment revenu increas
due acquisit bard compar currency-
neutral basi bd medic revenu increas prior-year
period segment result driven strong perform
medic manag solut pharmaceut system unit
bd life scienc segment revenu
compar currency-neutr basi exclud revenu associ
divest advanc bioprocess busi bd life scienc revenu
increas prior-year period revenu growth
driven strong perform preanalyt system unit
bd intervent segment revenu
compar currency-neutr basi revenu increas prior-
year period segment result reflect strong perform surgeri
urolog critic unit growth peripher intervent
unit reflect tough comparison prior-year period
deliv strong perform across three segment paid
debt gross leverag ratio declin
strong oper perform cost synergi captur drive sustain
margin expans bd new product pipelin remain track
start achiev measur bard revenu synergi
result due
acquisit bard
growth across
pipelin remain
track start
becton dickinson co februari
non- reconcili
non- reconcili
non- reconcili
oper tax oper tax becton dickinson co februari
incom statement
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
becton dickinson co februari
revenu growth ttm basi compar
ep growth ttm basi compar
oper margin ttm basi compar due increas sg
gross margin declin ttm basi compar due increas cog
ratio revenu margin margin inc margin rate margin turnov averag asset leverag averag equiti year averag averag averag year averag averag averag year averag averag averag growth growth ex sale /sale /net incom ratio profit marginsprofitabilityrevenu growth oper incom growthep growth becton dickinson co februari
mrqgross mrqoper mrqnet mrqcog mrqsg mrqr sale becton dickinson co februari
inv flow sale
mrqyoy growth revenu growthoper incom growthep mrq ratio growth yoy oper growth yoy free growth mrqcapex salescap ex salesfre mrqfinanci mrqreturn mrqreturn asset becton dickinson co februari
per share item ratio
fiscal per ebitda per ebit per earn per share ep ep free flow per dividend per book valu per tangibl book per month end stock month end stock equiti return asset return invest capit return capit joel greenblatt debt gross margin oper margin net margin total equiti total lt debt total asset dividend pay-out day sale day account day convers inventori cog inventori tax rate net incom net incom discontinued- net net margin prefer dividends- annual itemsquarterli item becton dickinson co februari
balanc sheet item
outstand equival market debt common prefer stock- purchas properti plant sale properti plant equipment- purchas sale business- purchas investment- sale issuanc stock- repurchas net issuanc prefer stock- net issuanc net chang capit free becton dickinson co februari
current price-to-earnings slightli averag price-to-earnings due fall stock price
quarter price-to-earnings trail averag octob price-to-earnings trail
avg-stdev past expect forward price-to-earnings multipl
bandp/eaverageavg stdevavg stdev becton dickinson co februari
incom statement
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
becton dickinson co februari
breakdown share held share held float held institut hold institut holdersholdersharesd report outvaluepric row associ vanguard group inc fmr jp morgan fundsmith well fargo putnam invest top mutual fund holdersholdersharesd report outvaluevanguard total stock market vanguard price row chip growth fund price row growth stock fund spdr etf franklin manag trust rise dividend fidel select portfolio medic technolog devic vanguard institut fund-institut price row capit appreci price row becton dickinson co februari
compani name/symbolcurr yr epsgrowthbecton dickinson minor becton dickinson co februari
developmentsbd launch ergonom needl technolog help optim inject techniquejanuari announc food drug administr clearanc second gener bd nano pen needl design reliabl subcutan inject depth bd nano gen pen needl offer peopl inject diabet medic reliabl subcutan deliveri medic design help peopl better manag diabet bd expand integr medic manag help tackl hospit drug diversionnovemb announc launch new softwar applic design help hospit health system identifi drug divers societi health-system pharmacist ashp midyear meet bd announc clinic trial data lutonix drug-coat balloon below-the-kne trialnovemb announc safeti efficaci data lutonixdrug-co balloon dcb level clinic trial below-the-kne btk indic bd launch molecular test detect tuberculosi multi-drug resist tboctob announc avail bd mdr-tb panel europ clinician use test simultan detect bacteria caus tuberculosi tb determin bacteria contain mutat associ resist two import first line drug isoniazid inh rifampicin rif enhanc inform avail direct optim treatment patient becton dickinson co februari
incom statement
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
becton dickinson co februari
compar
roa roi roe
actual vs price-to-earnings ratio ttm price-to-earnings high last yr price-to-earnings last yr beta price sale ttm price book mrq price ttm price free ttm errorerrorerror own dividend yield dividend yield year average dividend year growth rate pay-out ratio ttm sale mrq vs qtr yr sale ttm vs ttm yr sale yr growth rate sale yr growth rate ep mrq vs qtr yr ep ttm vs ttm yr ep yr growth rate ep yr growth rate capit spend yr growth rate lt debt equiti mrq total debt equiti mrq interest coverag ttm gross margin ttm gross margin yr average ebitd margin ttm ebitd yr average oper margin ttm oper margin yr average pre-tax margin ttm pre-tax margin yr average net profit margin ttm net profit margin yr average effect tax rate ttm effect tax rate yr average return asset ttm return asset yr average return invest ttm return invest yr average return equiti ttm return equiti yr average revenue/employe ttm net income/employe ttm receiv turnov ttm inventori turnov ttm asset turnov ttm manag effect effici performancevalu ratio dividend growth rate ratio profit becton dickinson co februari
consensu view analyst trend stock
forecast
compar
 average
multipl
compar
annual usdgrowth high day day day estim avgfive-year growth forecast comparisonbdxindustri avg avgprice/earn yield becton dickinson co februari
price target summarycrispidea trendscurr monthlast monthtwo month agothre month agostrong estcurr qtr next qtrcurrent yearnext estcurr qtr next qtrcurrent yearnext becton dickinson co februari
incom statement
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
becton dickinson co februari
stock price dip decemb surg januari
stock gave flat return period averag volum share trade
 price movementvolumeclos becton dickinson co februari
stock price show upward trend till septemb later declin volatil well
rang stock stock gave return year
 price movementvolumeclos becton dickinson co februari
stock price show upward trend past surg august
stock given return past due growth busi
 year price movementvolumeclos becton dickinson co februari
deliv strong perform growth revenu adjust ep
increas growth due acquisit bard strong growth across
busi segment recommend buy rate stock tp
closeci target becton dickinson co februari
crispidea financi inform servic firm focus provid equiti research portfolio manag
person wealth manag brokerag servic inform servic side provid commun
consult research servic host client
crispidea track limit number compani sector strive provid qualiti insight straight
forward analysi object creat long-term wealth moder low risk crispidea leverag
larg number in-hous extern expert oper within industri strong financi oper
strateg background
detail visit www crispidea com contact
